cbdMD Engages Leading Biotech Firm IONTOX to Validate Its Patent Pending Superior Broad Spectrum Blend
November 11 2020 - 04:06PM
Business Wire
Validation Creates Pathway For New
Water-Soluble Formulation For Beverages
cbdMD, Inc. (NYSE American: YCBD, YCBD.PR.A), one of the
nation’s leading and most highly trusted and recognized cannabidiol
(CBD) brands, announced today that it has retained nationally
recognized biotechnology company IONTOX (https://www.iontox.com),
to validate the Company’s patent pending proprietary cannabinoid
formulations. On July 9, 2020, cbdMD announced it had filed
provisional patents on its novel formulations and delivery systems.
This is the next step in demonstrating the safety and efficacy of
those formulations, including a new water-soluble formulation for
beverages.
“IONTOX has extensive expertise in in vitro technology which
utilizes novel techniques and testing methods for the safety of
botanical dietary ingredients. These analyses will provide valuable
insight to both current and future product formulation for cbdMD
and we are honored that such a respected company would select
IONTOX for this important research,” said Jim McKim, President of
IONTOX.
“As part of our ongoing science based approach, we are staying
ahead of current safety and testing methods by seeking to validate
our patent pending proprietary cannabinoid blends and delivery
systems. In addition to seeking FSA approval in the United Kingdom
and our preparations for an eventual NDIN submission to the FDA, we
are committed to the underlying science as demonstrated by our
partnership with IONTOX, who have worked with some of the biggest
names in research, such as: Dow, Unilever, Amway, Pfizer, Biogen
and L’Oréal Paris. Working with IONTOX not only helps cbdMD’s
regulatory submissions, but also demonstrates our commitment to
leading with science. We continue our commitment as a leader in the
development of innovative novel CBD products,” said Chairman &
Co-CEO, Martin A. Sumichrast.
About IONTOX
IONTOX is a biotechnology company founded in 2014 dedicated to
providing expertise to the area of in vitro toxicology, with a
mission to build improved methods for predicting human adverse
effects from chemical exposure. From laboratories located in
Kalamazoo, Michigan, IONTOX serves a global client base in the
pharmaceutical, cosmetic, chemical, tobacco, and food additive
industries. Through, consulting, product development, and
laboratory services the company contributes to the development,
application, and interpretation of alternative testing methods.
IONTOX aims to advance current alternative toxicology methods
through continuous efforts in the research and development of new
in vitro technology. Through the company’s contract research
laboratories IONTOX offers Advanced in vitro solutions that promise
to increase the reliability of in vitro toxicology.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading, most highly trusted, and most
recognized cannabidiol (CBD) brands, whose current products include
CBD tinctures, CBD capsules, CBD gummies, CBD topicals, CBD bath
bombs and CBD pet products. cbdMD is also a proud partner of
Bellator MMA and Life Time, Inc., and has one of the largest
rosters of professional sports athletes who are part of “Team
cbdMD.” To learn more about cbdMD and our comprehensive line of
over 100 SKUs of U.S. produced, Non-THC1 CBD products, please visit
www.cbdMD.com, follow cbdMD on Instagram and Facebook, or visit one
of the 6,000 retail outlets that carry cbdMD products.
1 Non-THC is defined as below the level of detection using
validated scientific analytical tools.
Forward-Looking Statements
This press release contains certain forward-looking statements
that are based upon current expectations and involve certain risks
and uncertainties within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements can
be identified by the use of words such as ''should,'' ''may,''
''intends,'' ''anticipates,'' ''believes,'' ''estimates,''
''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and
''proposes.'' These forward-looking statements are not guarantees
of future performance and are subject to risks, uncertainties, and
other factors, some of which are beyond our control and difficult
to predict and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
You are urged to carefully review and consider any cautionary
statements and other disclosures, including the statements made
under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on
Form 10-K for the fiscal year ended September 30, 2019 and Part II,
Item 1A. Risk Factors appearing in its Quarterly Report on Form
10-Q for the period ended June 30, 2020, both as filed with the
Securities and Exchange Commission (the "SEC") and our other
filings with the SEC. All forward-looking statements involve
significant risks and uncertainties that could cause actual results
to differ materially from those in the forward-looking statements,
many of which are generally outside the control of cbdMD, Inc. and
are difficult to predict. cbdMD, Inc. does not undertake any duty
to update any forward-looking statements except as may be required
by law. The information which appears on our websites and our
social media platforms, including, but not limited to, Instagram
and Facebook, is not part of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201111005861/en/
PR: cbdMD, Inc. Lauren Greene
Communications Specialist Lauren.Greene@cbdMD.com (843)
743-9999
Investors: cbdMD, Inc. John Weston
Director of Investor Relations John.Weston@cbdMD.com (704)
249-9515
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Feb 2024 to Mar 2024
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Mar 2023 to Mar 2024